1
|
Reyes-García J, Flores-Soto E, Carbajal-García A, Sommer B, Montaño LM. Maintenance of intracellular Ca2+ basal concentration in airway smooth muscle (Review). Int J Mol Med 2018; 42:2998-3008. [PMID: 30280184 PMCID: PMC6202086 DOI: 10.3892/ijmm.2018.3910] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Accepted: 09/18/2018] [Indexed: 01/07/2023] Open
Abstract
In airway smooth muscle, the intracellular basal Ca2+ concentration [b(Ca2+)i] must be tightly regulated by several mechanisms in order to maintain a proper airway patency. The b[Ca2+]i is efficiently regulated by sarcoplasmic reticulum Ca2+-ATPase 2b, plasma membrane Ca2+-ATPase 1 or 4 and by the Na+/Ca2+ exchanger. Membranal Ca2+ channels, including the L-type voltage dependent Ca2+ channel (L-VDCC), T-type voltage dependent Ca2+ channel (T-VDCC) and transient receptor potential canonical 3 (TRPC3), appear to be constitutively active under basal conditions via the action of different signaling pathways, and are responsible for Ca2+ influx to maintain b[Ca2+]i. The two types of voltage-dependent Ca2+ channels (L- and T-type) are modulated by phosphorylation processes mediated by mitogen-activated protein kinase kinase (MEK) and extracellular-signal-regulated kinase 1 and 2 (ERK1/2). The MEK/ERK signaling pathway can be activated by G-protein-coupled receptors through the αq subunit when the endogenous ligand (i.e., acetylcholine, histamine, leukotrienes, etc.) is present under basal conditions. It may also be stimulated when receptor tyrosine kinases are occupied by the appropriate ligand (cytokines, growth factors, etc.). ERK1/2 phosphorylates L-VDCC on Ser496 of the β2 subunit and Ser1928 of the α1 subunit, decreasing or increasing the channel activity, respectively, and enabling it to switch between an open and closed state. T-VDCC is also probably phosphorylated by ERK1/2, although further research is required to identify the phosphorylation sites. TRPC3 is directly activated by diacylglycerol produced by phospholipase C (PLCβ or γ). Constitutive inositol 1,4,5-trisphosphate production induces the release of Ca2+ from the sarcoplasmic reticulum through inositol triphosphate receptor 1. This ion induces Ca2+-induced Ca2+ release through the ryanodine receptor 2 (designated as Ca2+ ‘sparks’). Therefore, several Ca2+ handling mechanisms are finely tuned to regulate basal intracellular Ca2+ concentrations. It is conceivable that alterations in any of these processes may render airway smooth muscle susceptible to develop hyperresponsiveness that is observed in ailments such as asthma.
Collapse
Affiliation(s)
- Jorge Reyes-García
- Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México 04510, México
| | - Edgar Flores-Soto
- Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México 04510, México
| | - Abril Carbajal-García
- Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México 04510, México
| | - Bettina Sommer
- Departamento de Investigación en Hiperreactividad Bronquial, Instituto Nacional de Enfermedades Respiratorias, Ciudad de México 14080, México
| | - Luis M Montaño
- Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México 04510, México
| |
Collapse
|
4
|
Mannic T, Satta N, Pagano S, Python M, Virzi J, Montecucco F, Frias MA, James RW, Maturana AD, Rossier MF, Vuilleumier N. CD14 as a Mediator of the Mineralocorticoid Receptor-Dependent Anti-apolipoprotein A-1 IgG Chronotropic Effect on Cardiomyocytes. Endocrinology 2015; 156:4707-19. [PMID: 26393305 DOI: 10.1210/en.2015-1605] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
In vitro and animal studies point to autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) as possible mediators of cardiovascular (CV) disease involving several mechanisms such as basal heart rate interference mediated by a mineralocorticoid receptor-dependent L-type calcium channel activation, and a direct pro-inflammatory effect through the engagement of the toll-like receptor (TLR) 2/CD14 complex. Nevertheless, the possible implication of these receptors in the pro-arrhythmogenic effect of anti-apoA-1 antibodies remains elusive. We aimed at determining whether CD14 and TLRs could mediate the anti-apoA-1 IgG chronotropic response in neonatal rat ventricular cardiomyocytes (NRVC). Blocking CD14 suppressed anti-apoA-1 IgG binding to NRVC and the related positive chronotropic response. Anti-apoA-1 IgG alone induced the formation of a TLR2/TLR4/CD14 complex, followed by the phosphorylation of Src, whereas aldosterone alone promoted the phosphorylation of Akt by phosphatidylinositol 3-kinase (PI3K), without affecting the chronotropic response. In the presence of both aldosterone and anti-apoA-1 IgG, the localization of TLR2/TLR4/CD14 was increased in membrane lipid rafts, followed by PI3K and Src activation, leading to an L-type calcium channel-dependent positive chronotropic response. Pharmacological inhibition of the Src pathway led to the decrease of L-type calcium channel activity and abrogated the NRVC chronotropic response. Activation of CD14 seems to be a key regulator of the mineralocorticoid receptor-dependent anti-apoA-1 IgG positive chronotropic effect on NRVCs, involving relocation of the CD14/TLR2/TLR4 complex into lipid rafts followed by PI3K and Src-dependent L-type calcium channel activation.
Collapse
Affiliation(s)
- Tiphaine Mannic
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Nathalie Satta
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Sabrina Pagano
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Magaly Python
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Julien Virzi
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Fabrizio Montecucco
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Miguel A Frias
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Richard W James
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Andres D Maturana
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Michel F Rossier
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Nicolas Vuilleumier
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| |
Collapse
|
5
|
DeSantiago J, Bare DJ, Xiao L, Ke Y, Solaro RJ, Banach K. p21-Activated kinase1 (Pak1) is a negative regulator of NADPH-oxidase 2 in ventricular myocytes. J Mol Cell Cardiol 2014; 67:77-85. [PMID: 24380729 PMCID: PMC3930036 DOI: 10.1016/j.yjmcc.2013.12.017] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2013] [Revised: 12/19/2013] [Accepted: 12/21/2013] [Indexed: 12/20/2022]
Abstract
Ischemic conditions reduce the activity of the p21-activated kinase (Pak1) resulting in increased arrhythmic activity. Triggered arrhythmic activity during ischemia is based on changes in cellular ionic balance and the cells Ca(2+) handling properties. In the current study we used isolated mouse ventricular myocytes (VMs) deficient for the expression of Pak1 (Pak1(-/-)) to determine the mechanism by which Pak1 influences the generation of arrhythmic activity during simulated ischemia. The Ca(2+) transient amplitude and kinetics did not significantly change in wild type (WT) and Pak1(-/-) VMs during 15 min of simulated ischemia. However, Pak1(-/-) VMs exhibited an exaggerated increase in [Ca(2+)]i, which resulted in spontaneous Ca(2+) release events and waves. The Ca(2+) overload in Pak1(-/-) VMs could be suppressed with a reverse mode blocker (KB-R7943) of the sodium calcium exchanger (NCX), a cytoplasmic scavenger of reactive oxygen species (ROS; TEMPOL) or a RAC1 inhibitor (NSC23766). Measurements of the cytoplasmic ROS levels revealed that decreased Pak1 activity in Pak1(-/-) VMs or VMs treated with the Pak1 inhibitor (IPA3) enhanced cellular ROS production. The Pak1 dependent increase in ROS was attenuated in VMs deficient for NADPH oxidase 2 (NOX2; p47(phox-/-)) or in VMs where NOX2 was inhibited (gp91ds-tat). Voltage clamp recordings showed increased NCX activity in Pak1(-/-) VMs that depended on enhanced NOX2 induced ROS production. The exaggerated Ca(2+) overload in Pak1(-/-) VMs could be mimicked by low concentrations of ouabain. Overall our data show that Pak1 is a critical negative regulator of NOX2 dependent ROS production and that a latent ROS dependent stimulation of NCX activity can predispose VMs to Ca(2+) overload under conditions where no significant changes in excitation-contraction coupling are yet evident.
Collapse
Affiliation(s)
- Jaime DeSantiago
- Center for Cardiovascular Research, University of Illinois at Chicago, 840 S. Wood Street, Chicago, IL 60612, USA; Department of Medicine, Section of Cardiology, University of Illinois at Chicago, 840 S. Wood Street, Chicago, IL 60612, USA
| | - Dan J Bare
- Center for Cardiovascular Research, University of Illinois at Chicago, 840 S. Wood Street, Chicago, IL 60612, USA; Department of Medicine, Section of Cardiology, University of Illinois at Chicago, 840 S. Wood Street, Chicago, IL 60612, USA
| | - Lei Xiao
- Center for Cardiovascular Research, University of Illinois at Chicago, 840 S. Wood Street, Chicago, IL 60612, USA; Department of Medicine, Section of Cardiology, University of Illinois at Chicago, 840 S. Wood Street, Chicago, IL 60612, USA; Pulmonary, Critical Care, Sleep and Allergy, University of Illinois at Chicago, 840 S. Wood Street, Chicago, IL 60612, USA
| | - Yunbo Ke
- Center for Cardiovascular Research, University of Illinois at Chicago, 840 S. Wood Street, Chicago, IL 60612, USA; Department of Physiology and Biophysics, University of Illinois at Chicago, 840 S. Wood Street, Chicago, IL 60612, USA
| | - R John Solaro
- Center for Cardiovascular Research, University of Illinois at Chicago, 840 S. Wood Street, Chicago, IL 60612, USA; Department of Physiology and Biophysics, University of Illinois at Chicago, 840 S. Wood Street, Chicago, IL 60612, USA
| | - Kathrin Banach
- Center for Cardiovascular Research, University of Illinois at Chicago, 840 S. Wood Street, Chicago, IL 60612, USA; Department of Medicine, Section of Cardiology, University of Illinois at Chicago, 840 S. Wood Street, Chicago, IL 60612, USA.
| |
Collapse
|